- Home
- HDSN vs ADCT Comparison
HDSN vs ADCT Comparison
Compare HDSN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDSN
- ADCT
- Stock Information
- Founded
- HDSN 1991
- ADCT 2011
- Country
- HDSN United States
- ADCT Switzerland
- Employees
- HDSN N/A
- ADCT N/A
- Industry
- HDSN Industrial Specialties
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- HDSN Consumer Discretionary
- ADCT Health Care
- Exchange
- HDSN Nasdaq
- ADCT Nasdaq
- Market Cap
- HDSN 409.2M
- ADCT 454.5M
- IPO Year
- HDSN 1994
- ADCT 2020
- Fundamental
- Price
- HDSN $6.79
- ADCT $3.97
- Analyst Decision
- HDSN Strong Buy
- ADCT Strong Buy
- Analyst Count
- HDSN 2
- ADCT 6
- Target Price
- HDSN $9.50
- ADCT $7.60
- AVG Volume (30 Days)
- HDSN 378.8K
- ADCT 745.9K
- Earning Date
- HDSN 11-05-2025
- ADCT 11-10-2025
- Dividend Yield
- HDSN N/A
- ADCT N/A
- EPS Growth
- HDSN N/A
- ADCT N/A
- EPS
- HDSN 0.50
- ADCT N/A
- Revenue
- HDSN $236,847,000.00
- ADCT $75,209,000.00
- Revenue This Year
- HDSN $3.02
- ADCT $11.78
- Revenue Next Year
- HDSN $8.53
- ADCT $4.83
- P/E Ratio
- HDSN $13.52
- ADCT N/A
- Revenue Growth
- HDSN N/A
- ADCT 6.35
- 52 Week Low
- HDSN $5.11
- ADCT $1.05
- 52 Week High
- HDSN $10.52
- ADCT $4.80
- Technical
- Relative Strength Index (RSI)
- HDSN 26.94
- ADCT 45.58
- Support Level
- HDSN $6.45
- ADCT $3.87
- Resistance Level
- HDSN $7.36
- ADCT $4.19
- Average True Range (ATR)
- HDSN 0.41
- ADCT 0.30
- MACD
- HDSN -0.17
- ADCT -0.05
- Stochastic Oscillator
- HDSN 10.85
- ADCT 27.78
About HDSN Hudson Technologies Inc.
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).